Innovation Pharmaceuticals Inc (IPIX)

[frrol]

The K trial has been discontinued. Technically it failed; it wasn't producing results to justify completing the study. You don't pre-maturely end recruiting for successful trials of life-saving therapies (you do end trials for expedited approval, but not necessarily the enrollment and treatment). But it was producing hints of efficacy, so the company wants to focus on the oral K, out of clinical necessity; it's clear that IV K is an impracticality. The toxicology studies for oral K have been going for a year now, which is a good amount of time if they're using an experienced firm. We better hear about results soon and announcement of a Phase 1b. The company is optimistic.

Menon has lost half his salary and the company is cutting back on non-clinical staff. You don't want to hear that stuff. This means the company doesn't expect imminent cash flow from a B deal. BP is not gaga over our HDP-M platform. We've in fact shelved most of it (given back licenses to UoP). Hopefully we'll get a deal on B so we can move forward. It's go-time for that drug. Most of the 20+ CDAs are likely for B.

Strong P results are a bit more important now. We should be getting that data and announcing results in the next few weeks.